Resource use and costs in a Swedish cohort of patients with Parkinson's disease

Movement Disorders

Volumn 17, Issue 6, 2002, Pages 1213-1220

  Hagell, Peter ^a   Nordling, Sara ^b   Reimer, Jan ^a   Grabowski, Martin ^a   Persson, Ulf ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

Author keywords

Costs; Parkinson's disease; Resource use

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROLEPTIC AGENT; SELEGILINE; TRANQUILIZER;

ADULT; AGED; CALCULATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG COST; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OCCUPATIONAL THERAPY; OUTCOMES RESEARCH; PARKINSON DISEASE; PATIENT SATISFACTION; PHYSIOTHERAPY; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RESOURCE ALLOCATION; REVIEW; SWEDEN;

AGED; AGED, 80 AND OVER; COHORT STUDIES; COSTS AND COST ANALYSIS; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PARKINSON DISEASE; SWEDEN; UTILIZATION REVIEW;

EID: 0036869132     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10262     Document Type: Review

References (28)

1. Martinez-Martin P. An introduction to the concept of "quality of life in Parkinson's disease." J Neurol 1998;245(Suppl. 1):S2-S6.
2. Anell A, Willis M. International comparison of health care systems using resource profiles. Bull World Health Organ 2000;78:770-778.
3. Wise J. Global life expectancy rises. BMJ 1998;316:1477.
4. Dodel RC, Eggert K, Oertel WH. Economical research on Parkinson's disease: a review of the literature. Eur J Neurol 1999;6 (Suppl. 2):S3-S15.
5. Scheife RT, Schumock GT, Burstein A, Gottwold MD, Luer MS. Impact of Parkinson's disease and its pharmacological treatment on quality of life and economic outcomes. Am J Health Syst Pharm 2000;57:953-962.
6. Siderowf AD. Holloway RG, Stern MB. Cost-effectiveness analysis in Parkinson's disease: determining the value of interventions. Mov Disord 2000;15:439-445.
7. Hoehn MM, Yahr M. Parkinsonism: onset, progression and mortality. Neurology 1967;5:427-442.
8. Lindgren B. Cost of illness in Sweden 1964-1975 [dissertation]. Lund Economic Studies 24. Lund University, Sweden: Department of National Economics; 1981.
9. Hodgson TA. The state of the art of cost-of illness estimates. In: Scheffer RM, Rossister LF, editors. Advances in health economics and health services research. Vol. 4. Greenwich, Connecticut: JAI Press; 1983.
10. SCB. Befolkningsförändringar 1996: Del 4. Stockholm: Statistiska Centralbyrån; 1997.
11. LePen C, Wait S, Moutard-Martin F, Dujardin M, Ziégler M. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999;16:59-69.
12. Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman M. The burden of Parkinson's disease on society, family, and the individual. J Am Geriatr Soc 1997;45:844-849.
13. Fall PA, Axelson O, Fredriksson M, Hansson G, Lindvall B, Olsson JE, Granerus AK. Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community. J Clin Epidemiol 1996;49:637-641.
14. Aquilonius SM, Hartvig P. A Swedish county with unexpectedly high utilization of anti-Parkinsonian drugs. Acta Neurol Scand 1986;74:379-382.
15. Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Changing epidemiology of Parkinson's disease in southwestern Finland. Neurology 1999;52:302-308.
16. Tandberg E, Larsen JP, Nessler E.G., Riise T, Aarli JA. The epidemiology of Parkinson's disease in the county of Rogaland, Norway. Mov Disord 1995;10:541-549.
17. Wermuth L, von Weitzel-Mudersbach P, Jeune B. A two-fold difference in the age-adjusted prevalence of Parkinson's disease between the island of Als and the Faroe Islands. Eur J Neurol 2000; 7:655-660
18. Odin P, editor. Parkinsons sjukdom - Vårdprogram för södra sjukvårdsregionen 1996-98 [Parkinson's disease - Management program for the southern health care region]. Lund, Sweden, 1996.
19. Dodel RC, Singer M, Köhne-Volland R, Szucs T, Rathay B, Scholz E, Oertel WH. The economic impact of Parkinson's disease: an estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998;14:299-312.
20. Bain P, Baker M, Beech C, et al. The economic impact of Parkinson's disease: a primary care survey in the UK. The 4th European Parkinson's Disease Association Conference; Vienna, Austria: November 9-12, 2000 [abstract].
21. Anell A, Jönsson B, Persson U. Läkemedelskostnaderna. Lund: Institutet för hälso-och sjukvårdsekonomi, 1998.
22. Malmberg I, Persson U. Primärvårdskostnaderna för behandling av hjärtsvikt kartlagda: Ökad användning av ACE-hämmare skulle löna sig [Primary health care costs in connection with heart failure surveyed: increased use of ACE inhibitors would be beneficial]. Läkartidningen 2000;97:2465-2470.
23. Jonsson D, Husberg M. Socioeconomic costs of rheumatic diseases. Implications for technology assessment. Int J Technol Assess Health Care 2000;16:1193-1200.
24. Henriksson F, Agardh CD, Berne C, Bolinder J, Lonnqvist F, Stenstrom P, Ostenson CG, Jonsson B. Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med 2000;248: 387-396.
25. Henriksson F. The economic cost of multiple sclerosis in Sweden 1994. (IHE Working paper 1997:5). Lund, Sweden: The Swedish Institute for Health Economics; 1997.
26. Hoerger TJ, Bala MV, Rowland C, Greer M, Chrischilles EA, Holloway RG. Cost effectiveness of pramipexole in Parkinson's disease in the US. Pharmacoeconomics 1998;14:541-557.
27. Siderowf A, Holloway R, Mushlin A. Cost-effectiveness of pallidotomy and add-on medical therapy in Parkinson's disease. Ann Neurol 1998;44:517.
28. Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis. Neurology 2001;57:663-671.